检索范围：
排序： 展示方式：
可去除染料——N-聚糖多方法深入分析中的缺失环节 Article
Samanta Cajic, René Hennig, Valerian Grote, Udo Reichl, Erdmann Rapp
《工程（英文）》 2023年 第26卷 第7期 页码 132-150 doi: https://doi.org/10.1016/j.eng.2023.02.016
As the roles of glycans in health and disease continue to be unraveled, it is becoming apparent that glycans' immense complexity cannot be ignored. To fully delineate glycan structures, we developed an integrative approach combining a set of cost-effective, widespread, and easy-to-handle analytical methods. The key feature of our workflow is the exploitation of a removable fluorescent label—exemplified by 9-fluorenylmethyl chloroformate (Fmoc)—to bridge the gap between diverse glycoanalytical methods, especially multiplexed capillary gel electrophoresis with laser-induced fluorescence detection (xCGE-LIF) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Through the detailed structural analysis of selected, dauntingly complex N-glycans from chicken ovalbumin, horse serum, and bovine transferrin, we illustrate the capabilities of the presented strategy. Moreover, this approach "visualizes" N-glycans that have been difficult to identify thus far—such as the sulfated glycans on human immunoglobulin A—including minute changes in glycan structures, potentially providing useful new targets for biomarker discovery.
血清N-聚糖生物标志物诊断ALT水平正常慢性乙型肝炎患者显著肝纤维化和肝硬化的临床意义 Article
王林, 刘艺琪, 顾启馨, 张驰, 徐蕾, 王蕾, 陈翠英, 刘学恩, 赵鸿, 庄辉
《工程（英文）》 2023年 第26卷 第7期 页码 151-158 doi: 10.1016/j.eng.2023.03.008
本研究目的是探讨血清N-聚糖模型在285例丙氨酸转移酶（alanine aminotransferase, ALT）水平正常应用基于DNA测序仪的荧光糖电泳技术检测患者血清N-聚糖图谱，每例患者的血清样本中共鉴定出9个N-聚糖峰。），并比较血清N-聚糖模型和其他纤维化标志物的诊断效能。在诊断肝硬化（≥F5）时，血清N-聚糖RF-B模型的AUROC为0.97，与肝组织活检的符合率为88.94%。在ALT水平正常的慢性乙肝患者中，血清N-聚糖模型可作为诊断显著肝纤维化或肝硬化的潜在生物标志物。
人类蛋白质N-糖基化的十二年全基因组关联研究 Review
Anna Timoshchuk, Sodbo Sharapov, Yurii S. Aulchenko
《工程（英文）》 2023年 第26卷 第7期 页码 17-31 doi: 10.1016/j.eng.2023.03.013
Most human-secreted and membrane-bound proteins have covalently attached oligosaccharide chains, or glycans. Glycosylation influences the physical and chemical properties of proteins, as well as their biological functions. Unsurprisingly, alterations in protein glycosylation have been implicated in a growing number of human diseases, and glycans are increasingly being considered as potential therapeutic targets, an essential part of therapeutics, and biomarkers. Although glycosylation pathways are biochemically well-studied, little is known about the networks of genes that guide the cell- and tissue-specific regulation of these biochemical reactions in humans in vivo. The lack of a detailed understanding of the mechanisms regulating glycome variation and linking the glycome to human health and disease is slowing progress in clinical applications of human glycobiology. Two of the tools that can provide much sought-after knowledge of human in vivo glycobiology are human genetics and genomics, which offer a powerful data-driven agnostic approach for dissecting the biology of complex traits. This review summarizes the current state of human populational glycogenomics. In Section 1, we provide a brief overview of the N-glycan's structural organization, and in Section 2, we give a description of the major blood plasma glycoproteins. Next, in Section 3, we summarize, systemize, and generalize the results from current N-glycosylation genome-wide association studies (GWASs) that provide novel knowledge of the genetic regulation of the populational variation of glycosylation. Until now, such studies have been limited to an analysis of the human blood plasma N-glycome and the N-glycosylation of immunoglobulin G and transferrin. While these three glycomes make up a rather limited set compared with the enormous multitude of glycomes of different tissues and glycoproteins, the study of these three does allow for powerful analysis and generalization. Finally, in Section 4, we turn to genes in the established loci, paying particular attention to genes with strong support in Section 5. At the end of the review, in Sections 6 and 7, we describe special cases of interest in light of new discoveries, focusing on possible mechanisms of action and biological targets of genetic variation that have been implicated in human protein N-glycosylation.
范洪刚,顾菁,王亚琢,袁浩然,何明阳,孙富安
《中国工程科学》 2018年 第20卷 第3期 页码 102-108 doi: 10.15302/J-SSCAE-2018.03.015
羊种布鲁氏菌双抗原纳米结合疫苗的生物合成与免疫效果评估 Article
黄竞, 王玉飞, 王康丰, 李淑磊, 孙鹏, 郭艳, 刘建凯, 杨瑞馥, 曾明, 潘超, 王恒樑, 朱力
《工程（英文）》 2023年 第29卷 第10期 页码 95-109 doi: 10.1016/j.eng.2023.04.007
关键词： 蛋白-聚糖偶联技术（PGCT） 双抗原 纳米结合疫苗 羊种布鲁氏菌
人体前列腺特异性抗原携带含酮基-脱氧壬酮糖酸的N-聚糖 Article
Wei Wang, Tao Zhang, Jan Nouta, Peter A. van Veelen, Noortje de Haan, Theo M. de Reijke, Manfred Wuhrer, Guinevere S.M. Lageveen-Kammeijer
《工程（英文）》 2023年 第26卷 第7期 页码 119-131 doi: 10.1016/j.eng.2023.02.009
Ketodeoxynononic acid (Kdn) is a rather uncommon class of sialic acid in mammals. However, associations have been found between elevated concentrations of free or conjugated Kdn in relation to human cancer progression. Hitherto, there has been a lack of conclusive evidence that Kdn occurs on (specific) human glycoproteins (conjugated Kdn). Here, we report for the first time that Kdn is expressed on prostate-specific antigen (PSA) N-linked glycans derived from human seminal plasma and urine. Interestingly, Kdn was found only in an α2,3-linkage configuration on an antennary galactose, indicating a highly specific biosynthesis. This unusual glycosylation feature was also identified in a urinary PSA cohort in relation to prostate cancer (PCa), although no differences were found between PCa and non-PCa patients. Further research is needed to investigate the occurrence, biosynthesis, biological role, and biomarker potential of both free and conjugated Kdn in humans.
标题 作者 时间 类型 操作
京公网安备 11010502051620号
